Claims

1. Use of a therapeutic agent A and a therapeutic agent B in the manufacture of a medicament for a combination therapy for treating one or more of obesity, non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), polycystic ovary syndrome (PCOS), and hyperlipidemia in a subject, wherein the therapeutic agent A is a salicylate, and the therapeutic agent B is trimetazidine or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the combination therapy is for treating obesity, and wherein the obesity is visceral obesity or abdominal obesity.

3. The use of claim 1 or 2, wherein the subject is diagnosed with one or more of the following conditions:

(a) a fasting blood glucose or serum glucose concentration of greater than 110 mg/dL;

(b) a postprandial plasma glucose concentration of equal to or greater than 140 mg/dL;

(c) an HbA1c value of equal to or greater than 6.5%;

(d) obesity, visceral obesity, and/or abdominal obesity;

(e) a triglyceride blood concentration of equal to or greater than 150mg/dL;

(f) an HDL-cholesterol blood concentration of less than 40mg/dL in a female subject or an HDL-cholesterol blood concentration of less than 50mg/dL in a male subject;

(g) systolic blood pressure of equal to or greater than 130mmHg, and diastolic blood pressure of equal to or greater than 85mmHg; and

(h) an LDL-cholesterol blood concentration of equal to or greater than 130 mg/dL.

4. The use of any one of claims 1-3,

(i) wherein the subject is contraindicated in metformin monotherapy and/or intolerant to a therapeutic dose of metformin; and/or

(ii) wherein the subject is an individual with insufficient glycemic control after treatment with one or more antidiabetic drugs selected from the group consisting of:

(a) a biguanide;

(b) a sulfonylurea;

(c) a meglitinide;

(d) a thiazolidinedione;

(e) an alpha-glucosidase inhibitor;

(f) insulin;

(g) a dipeptidyl peptidase IV inhibitor;

(h) an SGLT2 inhibitor;

(i) a PPARα modulator;

(j) a glucose-dependent insulinotropic polypeptide agonist;

(k) a beta-3 agonist;

(l) GLP1;

(m) a PPARγ modulator; and

(n) an HMG-CoA reductase inhibitor.

5. The use of any one of claims 1-4, wherein the subject is a human.

6. The use of any one of claims 1-5, wherein the therapeutic agent A is aspirin.

7. The use of any one of claims 1-6,

i) wherein the weight ratio of the therapeutic agent A to the therapeutic agent B is from 1:1 to 10:1; and/or

ii) wherein the therapeutic agent A is at a daily dose of between 0.3 mg/kg and 120 mg/kg body weight, and the therapeutic agent B is at a daily dose of between 0.05 mg/kg and 500 mg/kg body weight.

8. The use of claim 7, wherein the weight ratio of the therapeutic agent A to the therapeutic agent B is 6:1.

9. The use of any one of claims 1-8, wherein the therapeutic agent A and the therapeutic agent B are for simultaneous administration.

10. The use of claim 9, wherein the therapeutic agent A and the therapeutic agent B are

contained in a single dosage form.

11. The use of any one of claims 1-8, wherein the therapeutic agent A and the therapeutic agent B are for sequential administration.

12. The use of claim 11, wherein the therapeutic agent A is for administration before the therapeutic agent B.

13. The use of claim 11, wherein the therapeutic agent A is for administration after the therapeutic agent B.

14. The use of any one of claims 1-13, wherein the therapeutic agent A and the therapeutic agent B are for oral or injection administration.

15. The use of any one of claims 1-14, wherein the combination therapy is for treating obesity.

16. The use of any one of claims 1 and 3-14, wherein the combination therapy is for the treatment of PCOS.

17. The use of any one of claims 1 and 3-14, wherein the combination therapy is for the treatment of NASH.

18. The use of any one of claims 1-17, wherein the therapeutic agent A and the therapeutic agent B are for administration one or more times per day.

19. The use of claim 18, wherein the therapeutic agent A and the therapeutic agent B are for administration once a day.